Citations

Clear

1790 citation(s) found for "Yu, Stephanie".

Complications and outcomes of posterior fossa decompression with duraplasty versus without duraplasty for pediatric patients with Chiari malformation type I and syringomyelia: a study from the Park-Reeves Syringomyelia Research Consortium
Akbari, S. Hassan A. , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Bauer, David F. , Bethel-Anderson, Tammy, Bierbrauer, Karin S. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Kaufman, Bruce A., Keating, Robert F., Khan, Nicklaus R., Krieger, Mark D., Leonard, Jeffrey R. , Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon , McEvoy, Sean D., Meehan, Thanda, Muhlbauer, Michael S., O’Neill, Brent R., Olavarria, Greg, Ragheb, John , Shannon, Chevis N. , Stone, Scellig , Strahle, Jennifer M. , Tamber, Mandeep S. , Torner, James C., Tuite, Gerald F. , Tyler‐Kabara, Elizabeth C. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Limbrick, David D. , Torner, James C. , Yahanda, Alexander T. , Ahmed, Raheel , Daniels, David J. , Dlouhy, Brian J , Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J., Jallo, George I. , Johnston, James M. , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Park, Tae Sung , Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | April 15, 2022 | Volume: 30 | Issue: 1 | Pages: 39-51

10.3171/2022.2.peds21446 | PMID 35426814 Get It

OBJECTIVE The aim of this study was to determine differences in complications and outcomes between posterior fossa decompression with duraplasty (PFDD) and without duraplasty (PFD) for the treatment of pediatric Chiari malformation type I (CM1) and syringomyelia (SM). METHODS The authors used retrospective and prospective components of the Park-Reeves Syringomyelia Research Consortium database to identify pediatric patients with CM1-SM who received PFD or PFDD and had at least 1 year of follow-up data. Preoperative, treatment, and postoperative characteristics were recorded and compared between groups. RESULTS A total of 692 patients met the inclusion criteria for this database study. PFD was performed in 117 (16.9%) and PFDD in 575 (83.1%) patients. The mean age at surgery was 9.86 years, and the mean follow-up time was 2.73 years. There were no significant differences in presenting signs or symptoms between groups, although the preoperative syrinx size was smaller in the PFD group. The PFD group had a shorter mean operating room time (p < 0.0001), fewer patients with > 50 mL of blood loss (p = 0.04), and shorter hospital stays (p = 0.0001). There were 4 intraoperative complications, all within the PFDD group (0.7%, p > 0.99). Patients undergoing PFDD had a 6-month complication rate of 24.3%, compared with 13.7% in the PFD group (p = 0.01). There were no differences between groups for postoperative complications beyond 6 months (p = 0.33). PFD patients were more likely to require revision surgery (17.9% vs 8.3%, p = 0.002). PFDD was associated with greater improvements in headaches (89.6% vs 80.8%, p = 0.04) and back pain (86.5% vs 59.1%, p = 0.01). There were no differences between groups for improvement in neurological examination findings. PFDD was associated with greater reduction in anteroposterior syrinx size (43.7% vs 26.9%, p = 0.0001) and syrinx length (18.9% vs 5.6%, p = 0.04) compared with PFD. CONCLUSIONS PFD was associated with reduced operative time and blood loss, shorter hospital stays, and fewer postoperative complications within 6 months. However, PFDD was associated with better symptom improvement and reduction in syrinx size and lower rates of revision decompression. The two surgeries have low intraoperative complication rates and comparable complication rates beyond 6 months.
Safety and Efficacy of Nebulized Zanamivir in Hospitalized Patients with Serious Influenza
Group, NIAID Collaborative Antiviral Study, Gnann, John W., Treanor, John J., Payá, Carlos V., Steigbigel, Roy T., Elliott, Michael J., Weiss, Heidi L. , Hayden, Frederick G. , Group, NIAID Collaborative Antiviral Study, Ison, Michael G. , Nagy-Agren, Stephanie E.

Mayo Clinic

Antiviral Therapy | April 14, 2022 | Volume: 8 | Issue: 3 | Pages: 183-190

10.1177/135965350300800301 Get It

Influenza is an important cause of hospitalization due to lower respiratory tract involvement for which there is no specific antiviral treatment with proven efficacy. We conducted a double-blind, randomized, placebo-controlled trial to assess the tolerability and efficacy of nebulized zanamivir (16 mg four times a day) in combination with rimantadine compared to rimantadine with nebulized saline for treating influenza in adults hospitalized with influenza. Twenty patients tolerated the inhaled zanamivir (ZNV) plus rimantadine without decline in peak expiratory flow rates compared to the 21 who received inhaled saline. The study was terminated early because the approval of ZNV made further enrolment untenable. No significant differences were observed in the proportion of patients shedding virus by treatment day 3 (57% ZNV plus rimantadine, 67% placebo plus rimantadine), or in the durations of hospitalization and supplemental oxygen use. More ZNV plus rimantadine recipients exhibited no or mild cough on day 3 of treatment (94 vs 55%, P=0.01). Two rimantadine-resistant viruses emerged during rimantadine monotherapy; no ZNV resistance was observed. Nebulized ZNV appears to be well tolerated in this hospitalized population but further studies are needed to assess its efficacy.
Risk of Early Versus Later Rebleeding From Dural Arteriovenous Fistulas With Cortical Venous Drainage
Durnford, Andrew , Akarca, Danyal , Culliford, David , Millar, John S. , Guniganti, Ridhima , Giordan, Enrico , Brinjikji, Waleed , Chen, Ching‐Jen , Abecassis, Isaac Josh , Levitt, Michael R. , Polifka, Adam , Derdeyn, Colin P. , Kwasnicki, Amanda , Alaraj, Ali , Potgieser, Adriaan R. E., Tada, Yoshiteru , Abla, Adib A. , Satomi, Junichiro, Starke, Robert M., Dijk, J. Marc C. van , Amin‐Hanjani, Sepideh , Hayakawa, M. , Gross, Bradley A. , Kim, Louis J. , Sheehan, Jason P. , Kansagra, Akash P. , Lai, Rosalind, Zipfel, Gregory J. , Bulters, Diederik , Piccirillo, Jay F. , Vine, Roanna , Cloft, Harry J. , Kallmes, David F. , Pollock, Bruce E. , Link, Michael J. , Patibandla, Mohana Rao, Ding, Dale , Buell, Thomas J. , Paisan, Gabriella, Meyer, R. Michael, Kelly, Cory , Duffill, Jonathan, Ditchfield, Adam, Macdonald, Jason, Laurent, Dimitri , Lockerman, Ashley, Lunsford, L. Dade , Jankowitz, Brian T. , Guerrero, Waldo R. , McGruder, Allen, Charbel, Fady T. , Aletich, Victor , Rose‐Finnell, Linda, Peterson, Eric C. , Yavagal, Dileep R. , Sur, Samir , Kanematsu, Yasuhisa , Kinouchi, T. , Korai, Masaaki , Yamaguchi, Izumi , Yamamoto, Yuki , Winkler, Ethan A. , Lawton, Michael T. , Rutkowski, Martin J. , Sultan, M. Ali Aziz, Patel, Nirav , Frerichs, Kai U., Levitt, Michael R , Polifka, Adam J , Samaniego, Edgar A , Alaraj, Ali , Tada, Yoshiteru , Phelps, Ryan , Abla, Adib , van DijK, J Marc C , Amin-Hanjani, Sepideh , Gross, Bradley , Fox, W Christopher , Kim, Louis J. , Sheehan, Jason , Lanzino, Giuseppe , Kansagra, Akash P , Du, Rose , Lai, Rosalind , Zipfel, Gregory J , Bulters, Diederik O , Ding, Dale , Chen, Ching-Jen , Derdeyn, Colin P , Abecassis, Isaac Josh , Millar, John, Chen, Stephanie , Lanzino, Giuseppe , Raman, Hari S. , Lipsey, Kim L. , Hoh, Brian L. , Smith, Jessica , Ortega-Gutierrez, Santiago , Hasan, David , Roa, Jorge A. , Rossen, James D. , Yamamoto, Nobuaki

Mayo Clinic

Stroke | April 14, 2022 | Volume: 53 | Issue: 7 | Pages: 2340-2345

10.1161/strokeaha.121.036450 | PMID 35420453 Get It

Background: Cranial dural arteriovenous fistulas with cortical venous drainage are rare lesions that can present with hemorrhage. A high rate of rebleeding in the early period following hemorrhage has been reported, but published long-term rates are much lower. No study has examined how risk of rebleeding changes over time. Our objective was to quantify the relative incidence of rebleeding in the early and later periods following hemorrhage. Methods: Patients with dural arteriovenous fistula and cortical venous drainage presenting with hemorrhage were identified from the multinational CONDOR (Consortium for Dural Fistula Outcomes Research) database. Natural history follow-up was defined as time from hemorrhage to first treatment, rebleed, or last follow-up. Rebleeding in the first 2 weeks and first year were compared using incidence rate ratio and difference. Results: Of 1077 patients, 250 met the inclusion criteria and had 95 cumulative person-years natural history follow-up. The overall annualized rebleed rate was 7.3% (95% CI, 3.2–14.5). The incidence rate of rebleeding in the first 2 weeks was 0.0011 per person-day; an early rebleed risk of 1.6% in the first 14 days (95% CI, 0.3–5.1). For the remainder of the first year, the incidence rate was 0.00015 per person-day; a rebleed rate of 5.3% (CI, 1.7–12.4) over 1 year. The incidence rate ratio was 7.3 (95% CI, 1.4–37.7; P , 0.026). Conclusions: The risk of rebleeding of a dural arteriovenous fistula with cortical venous drainage presenting with hemorrhage is increased in the first 2 weeks justifying early treatment. However, the magnitude of this increase may be considerably lower than previously thought. Treatment within 5 days was associated with a low rate of rebleeding and appears an appropriate timeframe.
Post-COVID-19 syndrome: persistent neuroimaging changes and symptoms 9 months after initial infection
Grach, Stephanie L. , Ganesh, Ravindra , Messina, Steven A. , Hurt, Ryan T. , Ganesh, Ravindra , Grach, Stephanie L

Mayo Clinic

BMJ Case Reports | April 8, 2022 | Volume: 15 | Issue: 4 | Pages: e248448

10.1136/bcr-2021-248448 | PMID 35396239 Get It

A previously healthy and active middle-aged woman acquired COVID-19 as an occupational exposure with subsequent persistent post-COVID-19 symptoms including headache, dyspnoea on exertion, chest pressure, tachycardia, anosmia, parosmia, persistent myalgia, vertigo, cognitive decline and fatigue. She presented to a tertiary medical centre for further evaluation after 9 months of persistent symptoms and had a largely unremarkable workup with the exception of a persistently elevated monocyte chemoattractant protein 1, blunted cardiovagal response and non-specific scattered areas of low-level hypometabolism at the bilateral frontal, left precuneus, occipital and parietal regions on PET scan.
Incidence, prevalence and mortality of chronic periaortitis: a population-based study
Ghaffar, Umar , Duong, Stephanie Q. , Crowson, Cynthia S. , Burke, Michelle, Potretzke, Aaron M. , Burke, Michelle M, Viers, Boyd R. , Bjarnason, Haraldur , Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Clinical and Experimental Rheumatology | April 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/0v8l4j | PMID 35200130 Get It

Abstract P125: Change In Low-density Lipoprotein Cholesterol And Risk Of Subsequent Cardiovascular Events Among Patients With Myocardial Infarction
Manemann, Sheila M., Reading, Stephanie , Noshad, Sina , Weston, Susan A., Killian, Jill M. , Cohen, Sarah S. , Movva, Naimisha , Chamberlain, Alanna M.

Mayo Clinic

Circulation | April 7, 2022 | Volume: 145 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.145.suppl_1.p125 Get It

Background: Among patients who experience a myocardial infarction (MI), elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for experiencing a subsequent cardiovascular (CV) event; however, real-world evidence is lacking in regard to how changes in LDL-C levels after a MI hospitalization are related to subsequent CV events. Methods: Adults with a hospitalized MI and an available baseline LDL-C (closest LDL-C within 2 years prior to hospital discharge) between 2012 and 2018 within a 27-county region across MN and WI were included for study. For each LDL-C measurement during follow-up (starting with the first LDL-C >30 days after baseline and ≤1-year post-discharge), percent change from baseline LDL-C was calculated. Patients were followed for subsequent CV events (composite endpoint 1: MI, ischemic stroke [IS], coronary artery bypass grafting [CABG], percutaneous coronary intervention [PCI]; composite endpoint 2: MI, IS, CABG, PCI, CV death). Cox models were used to evaluate the association between time-dependent LDL-C percent change and CV events, stratified by baseline LDL-C (<70, 70-99, ≥100 mg/dL). Results: Among 3,034 MI patients identified, 740 (24%), 940 (31%) and 1354 (45%) had a baseline LDL-C <70, 70-99 and ≥100 mg/dL, respectively. After a mean follow-up of 3.4 years, 471 and 667 patients experienced the composite endpoint 1 and 2, respectively. After covariate adjustment, a trend towards a lower risk of CV events with decreasing LDL-C from baseline, compared to those with no change or an increase in LDL-C, was observed among those with a LDL-C <70 and > 100 mg/dl but not in those with a LDL-C 70-99 mg/dL (Table). Conclusions: In a population-based cohort of MI patients, there is evidence that patients with a decrease in LDL-C after MI may have a reduced risk of subsequent CV events. These results underscore the importance of lowering LDL-C after a MI and may help to identify subgroups at highest risk for additional CV events and those who may benefit from targeted LDL-C treatment recommendations.
Feasibility of Instituting a Clinical Otolaryngology Human Papillomavirus (HPV) Vaccination Program
Palacios, Victoria J. , Merlino, Dante J. , Anderson, Stephanie S., Yeakel, Sarah R., Wiedermann, Joshua P. , Moore, Eric J. , O’Byrne, Thomas J., Abel, Kathryn M. Van , Choby, Garret , Moore, Eric J , O'Byrne, Thomas J, Jacobson, Robert M. , Van Abel, Kathryn M , Yeakel, Sarah, Choby, Garret

Mayo Clinic

The Laryngoscope | April 2, 2022 | Volume: 133 | Issue: 1 | Pages: 116-123

10.1002/lary.30130 | PMID 35366006 Get It

ObjectivesTo measure baseline human papillomavirus (HPV) vaccination rates among tertiary and community‐based Otolaryngology – Head and Neck Surgery (Oto‐HNS) clinic patients and to determine risk factors for under‐vaccination.MethodsRetrospective chart review of patients aged 9 to 26 years presenting to an Oto‐HNS clinic from 2017 to 2019. Patients were considered complete for HPV vaccination if they received two doses of HPV vaccine with the first dose received before age 15 years or three doses of HPV vaccine otherwise.Results8,532 unique patients met the criteria. At the index visit, 3,110 (36.5%) had completed the HPV series, 5,422 (63.5%) were due for one or more doses, with 4,981 (58.4%) eligible for vaccination at the time of their appointment. Of those dues, most (3,148/5,422 or 58%) were past due by age (≥13 years old). Of the 3,148 patients past due, 745 (23.7%) were partially vaccinated and 2,403 (76.3%) were vaccine naïve. Male sex and younger age were both independently associated with incomplete vaccination (p < 0.0001).ConclusionThis study demonstrates that the implementation of on‐site HPV vaccination has the potential to increase the opportunities for vaccination among vaccine‐eligible patients, especially among young males. Otolaryngologists have the potential to provide meaningful preventive services in the fight against HPV‐mediated disease.Level of Evidence3 Laryngoscope, 133:116–123, 2023
Virtual Reality for Health Care Professionals During a Pandemic: A Pilot Program
Croghan, Ivana T. , Aakre, Christopher A. , Fokken, Shawn C. , Lindeen, Stephanie A. , Schroeder, Darrell R. , Ganesh, Ravindra , Ghosh, Karthik, Bauer, Brent A. , Hurt, Ryan T. , Lindeen, Stephanie A , Ganesh, Ravindra , Schroeder, Darrell , Fischer, Karen M.

Mayo Clinic

Journal of Primary Care & Community Health | March 30, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221086716 | PMID 35352605 Get It

Objective: The purpose of this pilot study was to evaluate the safety and use of a nature-based virtual reality (VR) experience among health care providers (HCP) during a pandemic. Methods: Twenty-four frontline HCP participated in this crossover pilot where the viewing order of the experiences were randomized. All participants attended in-person consent, baseline, and end-of-study visits. The intervention consisted of viewing 2 nature-based scenes (“walk in the woods” and “forest of focus”) through 3-D VR and with computer 4K graphic imagery. Randomization took place with regards to the viewing order (VR vs 4K computer video, scene 1 and 2). Outcomes measured were safety, acceptability and changes in intensity of anxiety feelings, resilience, emotional distress, cognitive function, and self-efficacy. Results: Among the 26 HCP expressing interest in the study, 24 enrolled in this study. The majority were male (58.3%), white (66.7%) and of an average age of 46.3 ± 10.5 years (standard deviation (SD)). End of the study survey showed that almost all participants (96%) would participate in the study again and recommend it to others. Twenty-three of the 24 participants also felt relaxed after seeing the imagery. With respect to anxiety (as measured by the STAI Y1), the VR “walk in the woods” had the greatest reduction from pre to post (6.4 points, SD = 5.98) followed by VR “forest of focus” (5.8 points, SD = 9.29), computer screen “forest of focus” (5.0 points, SD = 8.89), and computer screen “walk in the woods” (4.1 points, SD = 6.22). All 4 sessions had a significant decrease in score from pre to post (P-values ≤.005), but there was no significant difference in the change from pre- to post-session between the 4 groups (P-value = .5835). Conclusion: The use of the VR among HCP has promise for reducing stress among health care providers during a high stress period, such as a pandemic but much larger studies are needed.
Pseudoaneurysm of the Dorsalis Pedis Artery Following Open Reduction and Internal Fixation of a Second Metatarsal Fracture: A Case Study
Kvas, Stephanie P., Jorgensen, Scott F.

Mayo Clinic

Journal of the American Podiatric Medical Association | March 23, 2022 | Volume: 112 | Issue: 6 | Pages: No page available

10.7547/20-201 | PMID 36459069 Get It

Pseudoaneurysms are created by a traumatic or iatrogenic perforation of an artery, resulting in accumulation of blood between the two outermost layers of a blood vessel, the tunica media and tunica adventitia. Pedal artery pseudoaneurysms are an extremely uncommon complication of foot and ankle surgery; therefore, few cases have been reported in the literature. Early diagnosis is important to ensure timely treatment of this condition. Once clinical suspicion has been established, urgent referral to the vascular surgery clinic for prompt surgical evaluation is required to prevent potentially harmful sequelae. We present the case of a 70-year-old woman who developed a pseudoaneurysm of the dorsalis pedis artery 33 days after undergoing open reduction and internal fixation of a second metatarsal fracture. Her treatment included urgent referral to the vascular surgery clinic with subsequent surgical repair of the pseudoaneurysm by means of ligation of the medial dorsal branch of the dorsalis pedis artery. At 10-month follow-up, she denied any pain, sensory deficits, or functional disability and had returned to all preinjury activities, with no recurrence of the pseudoaneurysm. Our case study demonstrates early diagnosis and successful treatment of a pseudoaneurysm of the dorsalis pedis artery that developed shorty after open reduction and internal fixation of a second metatarsal fracture.
Social Media and Professional Development for Oncology Professionals
Chidharla, Anusha , Attai, Deanna J. , Drake, Emily K. , Londen, G. J. van , Subbiah, Ishwaria M. , Henry, Elizabeth , Murphy, Martina, Barry, Maura , Manochakian, Rami , Leyfman, Yan , Utengen, Audun , Attai, Deanna J , Drake, Emily K , van Londen, G J , Subbiah, Ishwaria M , Henry, Elizabeth , Barry, Maura M , Manochakian, Rami , Moerdler, Scott , Loeb, Stacy , Graff, Stephanie L , Leyfman, Yan , Thompson, Michael A , Markham, Merry J , Utengen, Audun , Loeb, Stacy , Graff, Stephanie L. , Thompson, Michael A, Markham, Merry Jennifer

Mayo Clinic

JCO Oncology Practice | March 21, 2022 | Volume: 18 | Issue: 8 | Pages: 566-571

10.1200/op.21.00761 | PMID 35312343 Get It

The use of social media continues to increase in health care and academia. Health care practice, particularly the oncologic field, is constantly changing because of new knowledge, evidence-based research, clinical trials, and government policies. Therefore, oncology trainees and professionals continue to strive to stay up-to-date with practice guidelines, research, and skills. Although social media as an educational and professional development tool is no longer completely new to medicine and has been embraced, it is still under-researched in terms of various outcomes. Social media plays several key roles in professional development and academic advancement. We reviewed the literature to evaluate how social media can be used for professional development and academic promotion of oncology professionals.